Vas Narasimhan

CEO, Novartis
· tracked since Jul 2026
Calls
1
Win Rate
0.0%
return
-0.5%
Calls 1 2 Posts tracked · 1.0/day
Calls
7d 1
30d 1
90d 1
Best Calls
No live winners yet
Worst Calls
NVS Long -0.5%
Most Mentioned
NVS ×2
Recent Calls
NVS Long 1 day ago
Win Rate 0% Long 1 Short 0
Win Rate
7d —
30d —
90d —
Average Return -0.5% Long Return -0.5% Short Return -
Average Return
7d —
30d —
90d —
Loading charts...
Result
Result
Sort
Theme Stance
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
NVS Novartis AG Novartis AG
Long
Jul 21
$153.87
-0.5%
Novartis growth pipeline underappreciated.
Novartis expects sustained 5-6% annual growth through 2030, supported by strong oncology and cardiovascular drugs, upcoming pipeline catalysts (remibrutinib, deldesiran) that could upgrade guidance, and an underappreciated growth runway with radio ligand therapy infrastructure creating a competitive moat.
Pharma & Biotech
YOUTUBE
Showing 1 of 1 calls · sorted by mentions

Vas Narasimhan has 1 trade ideas tracked on Buzzberg across 1 tickers since July 2026. Most covered: NVS.